Oncology Corporate Profile
Oxis Biotech is an immuno-oncology focused company developing innovative drugs focused on the treatment of cancer and other unmet medical needs. OXIS' lead drug candidate, OXS-1550 (DT2219ARL), is a novel bispecific scFv recombinant fusion protein-drug conjugate composed of the variable regions of the heavy and light chains of anti-CD19 and anti-CD22 antibodies and a modified form of diphtheria toxin as its cytotoxic drug payload. OXS-1550 targets cancer cells expressing the CD19 receptor or CD22 receptor or both receptors.
3/31/2017 08:00 pm
3/23/2017 09:01 pm
3/23/2017 12:00 pm
[Accesswire] - LOS ANGELES, CA / ACCESSWIRE / March 23, 2017 / Oxis International Inc. (OTCQB: OXIS and Euronext Paris OXI.PA) announced today that it has entered into a sponsored research agreement with the University ...
3/21/2017 12:00 pm
[Accesswire] - LOS ANGELES, CA / ACCESSWIRE / March 21, 2017 / Oxis International Inc. (OTCQB: OXIS) ( Euronext Paris OXI.PA ) announced today that Dr. Daniel Vallera, a member of the Scientific Advisory Board of its ...
2/21/2017 01:01 pm
[Accesswire] - TAMPA, FL / ACCESSWIRE / February 21, 2017 / Oxis International, Inc. (OTCQB: OXIS) (OXIS.PA) parent company of Oxis Biotech, focused on the development and commercialization of immunotherapy for the treatment ...
2/17/2017 10:01 pm